vs
CHAMPIONS ONCOLOGY, INC.（CSBR）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
CHAMPIONS ONCOLOGY, INC.的季度营收约是RIVERVIEW BANCORP INC的1.1倍（$15.0M vs $14.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs 1.8%，领先8.0%），CHAMPIONS ONCOLOGY, INC.同比增速更快（11.5% vs 10.4%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-2.0M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs 11.8%）
冠军肿瘤学公司是一家成立于2007年的美国科技企业，由约翰霍普金斯大学肿瘤学家David Sidransky博士创立。该公司开发名为TumorGrafts的小鼠模型（又称小鼠化身），可用于测试多种化疗方案、靶向药物与单克隆抗体，帮助为癌症患者筛选潜在的可行治疗方案。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
CSBR vs RVSB — 直观对比
营收规模更大
CSBR
是对方的1.1倍
$14.0M
营收增速更快
CSBR
高出1.1%
10.4%
净利率更高
RVSB
高出8.0%
1.8%
自由现金流更多
RVSB
多$1.2M
$-2.0M
两年增速更快
RVSB
近两年复合增速
11.8%
损益表 — Q2 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $15.0M | $14.0M |
| 净利润 | $268.0K | $1.4M |
| 毛利率 | 51.7% | — |
| 营业利润率 | 1.2% | 12.4% |
| 净利率 | 1.8% | 9.8% |
| 营收同比 | 11.5% | 10.4% |
| 净利润同比 | -63.2% | 11.8% |
| 每股收益（稀释后） | $0.02 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSBRRVSB
| Q4 25 | $15.0M | $14.0M | ||
| Q3 25 | $14.0M | $13.6M | ||
| Q2 25 | $12.4M | $13.3M | ||
| Q1 25 | $17.0M | $12.9M | ||
| Q4 24 | $13.5M | $12.7M | ||
| Q3 24 | $14.1M | $12.8M | ||
| Q2 24 | $14.0M | $12.2M | ||
| Q1 24 | $12.0M | $9.0M |
净利润CSBRRVSB
| Q4 25 | $268.0K | $1.4M | ||
| Q3 25 | $-436.0K | $1.1M | ||
| Q2 25 | $-1.8M | $1.2M | ||
| Q1 25 | $4.5M | $1.1M | ||
| Q4 24 | $728.0K | $1.2M | ||
| Q3 24 | $1.3M | $1.6M | ||
| Q2 24 | $-109.0K | $966.0K | ||
| Q1 24 | $-2.5M | $-3.0M |
毛利率CSBRRVSB
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
营业利润率CSBRRVSB
| Q4 25 | 1.2% | 12.4% | ||
| Q3 25 | -3.8% | 10.2% | ||
| Q2 25 | -16.2% | 11.7% | ||
| Q1 25 | 26.4% | 11.3% | ||
| Q4 24 | 5.4% | 12.4% | ||
| Q3 24 | 9.5% | 15.5% | ||
| Q2 24 | -1.9% | 10.0% | ||
| Q1 24 | -21.4% | -47.5% |
净利率CSBRRVSB
| Q4 25 | 1.8% | 9.8% | ||
| Q3 25 | -3.1% | 8.1% | ||
| Q2 25 | -14.9% | 9.2% | ||
| Q1 25 | 26.4% | 8.9% | ||
| Q4 24 | 5.4% | 9.7% | ||
| Q3 24 | 9.3% | 12.2% | ||
| Q2 24 | -0.8% | 7.9% | ||
| Q1 24 | -21.1% | -34.7% |
每股收益（稀释后）CSBRRVSB
| Q4 25 | $0.02 | $0.07 | ||
| Q3 25 | $-0.03 | $0.05 | ||
| Q2 25 | $-0.12 | $0.06 | ||
| Q1 25 | $0.31 | $0.05 | ||
| Q4 24 | $0.05 | $0.06 | ||
| Q3 24 | $0.09 | $0.07 | ||
| Q2 24 | $-0.01 | $0.05 | ||
| Q1 24 | $-0.19 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.2M | $164.2M |
| 总资产 | $30.2M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSBRRVSB
| Q4 25 | $8.5M | $28.6M | ||
| Q3 25 | $10.3M | $32.8M | ||
| Q2 25 | $9.8M | $34.2M | ||
| Q1 25 | $3.2M | $29.4M | ||
| Q4 24 | $2.8M | $25.3M | ||
| Q3 24 | $2.9M | $31.0M | ||
| Q2 24 | $2.6M | $27.8M | ||
| Q1 24 | $4.5M | $23.6M |
股东权益CSBRRVSB
| Q4 25 | $4.2M | $164.2M | ||
| Q3 25 | $3.5M | $163.5M | ||
| Q2 25 | $3.8M | $162.0M | ||
| Q1 25 | $5.5M | $160.0M | ||
| Q4 24 | $681.0K | $158.3M | ||
| Q3 24 | $-332.0K | $160.8M | ||
| Q2 24 | $-1.9M | $155.9M | ||
| Q1 24 | $-2.1M | $155.6M |
总资产CSBRRVSB
| Q4 25 | $30.2M | $1.5B | ||
| Q3 25 | $30.5M | $1.5B | ||
| Q2 25 | $32.3M | $1.5B | ||
| Q1 25 | $30.6M | $1.5B | ||
| Q4 24 | $25.2M | $1.5B | ||
| Q3 24 | $24.9M | $1.5B | ||
| Q2 24 | $26.1M | $1.5B | ||
| Q1 24 | $26.8M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $-736.0K |
| 自由现金流率自由现金流/营收 | -13.1% | -5.2% |
| 资本支出强度资本支出/营收 | 1.6% | 1.6% |
| 现金转化率经营现金流/净利润 | -6.47× | -0.37× |
| 过去12个月自由现金流最近4个季度 | $5.6M | $20.4M |
8季度趋势，按日历期对齐
经营现金流CSBRRVSB
| Q4 25 | $-1.7M | $-506.0K | ||
| Q3 25 | $600.0K | $16.8M | ||
| Q2 25 | $6.9M | $-697.0K | ||
| Q1 25 | $490.0K | $8.3M | ||
| Q4 24 | $-283.0K | $2.2M | ||
| Q3 24 | $311.0K | $764.0K | ||
| Q2 24 | $-1.8M | $5.4M | ||
| Q1 24 | $-919.0K | $12.8M |
自由现金流CSBRRVSB
| Q4 25 | $-2.0M | $-736.0K | ||
| Q3 25 | $554.0K | $16.4M | ||
| Q2 25 | $6.6M | $-773.0K | ||
| Q1 25 | $448.0K | $5.6M | ||
| Q4 24 | $-377.0K | $1.9M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | $-1.8M | $5.3M | ||
| Q1 24 | $-1.0M | $7.1M |
自由现金流率CSBRRVSB
| Q4 25 | -13.1% | -5.2% | ||
| Q3 25 | 4.0% | 120.1% | ||
| Q2 25 | 53.5% | -5.8% | ||
| Q1 25 | 2.6% | 43.1% | ||
| Q4 24 | -2.8% | 15.0% | ||
| Q3 24 | — | -11.3% | ||
| Q2 24 | -13.0% | 43.7% | ||
| Q1 24 | -8.4% | 79.0% |
资本支出强度CSBRRVSB
| Q4 25 | 1.6% | 1.6% | ||
| Q3 25 | 0.3% | 2.9% | ||
| Q2 25 | 2.0% | 0.6% | ||
| Q1 25 | 0.2% | 21.0% | ||
| Q4 24 | 0.7% | 2.4% | ||
| Q3 24 | 0.0% | 17.3% | ||
| Q2 24 | 0.0% | 0.9% | ||
| Q1 24 | 0.8% | 62.0% |
现金转化率CSBRRVSB
| Q4 25 | -6.47× | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | 0.11× | 7.20× | ||
| Q4 24 | -0.39× | 1.79× | ||
| Q3 24 | 0.24× | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
RVSB
暂无分部数据
